Coexistence of dementia with smear-positive pulmonary tuberculosis is associated with patient in-hospital mortality.


Journal

Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 10 09 2018
revised: 12 01 2019
accepted: 21 01 2019
pubmed: 15 2 2019
medline: 15 1 2020
entrez: 15 2 2019
Statut: ppublish

Résumé

The impact of dementia on the survival of patients with pulmonary tuberculosis (TB) remains unclear. This study sought to describe the risk factors influencing in-hospital mortality in patients with pulmonary TB and comorbid dementia. A 9-y, medical record-based retrospective study of hospitalized adult patients with newly diagnosed, smear-positive, non-multidrug-resistant pulmonary TB without human immunodeficiency virus infection was performed. Clinical presentations, biochemical tests, radiographic findings, and clinical outcomes were collected. Variables were compared between groups. Statistically significant (p-value < 0.05) variables were entered into a multivariate stepwise logistic regression model. Survival analysis was performed using the Kaplan-Meier method, and groups were compared by log-rank test. Of the 279 enrolled patients (178 men; median age, 76 y), the mortality rate was 12.2% (34/279). Univariate analysis showed a higher frequency of dementia in patients who died in hospital than that in surviving patients. Multivariate stepwise logistic analysis showed that dementia was significantly associated with higher rates of in-hospital mortality (odds ratio, 3.20; 95% confidence interval, 1.15-8.88, p = 0.026). In addition, subgroup survival curves showed that dementia was associated with reduced survival rates, even after adjusting for age (log-rank test, p = 0.0007). The comorbidity of dementia with pulmonary TB was associated with patient in-hospital mortality. Medical practitioners should be aware of dementia in patients with smear-positive pulmonary TB to identify high-mortality groups.

Sections du résumé

BACKGROUND BACKGROUND
The impact of dementia on the survival of patients with pulmonary tuberculosis (TB) remains unclear. This study sought to describe the risk factors influencing in-hospital mortality in patients with pulmonary TB and comorbid dementia.
METHODS METHODS
A 9-y, medical record-based retrospective study of hospitalized adult patients with newly diagnosed, smear-positive, non-multidrug-resistant pulmonary TB without human immunodeficiency virus infection was performed. Clinical presentations, biochemical tests, radiographic findings, and clinical outcomes were collected. Variables were compared between groups. Statistically significant (p-value < 0.05) variables were entered into a multivariate stepwise logistic regression model. Survival analysis was performed using the Kaplan-Meier method, and groups were compared by log-rank test.
RESULTS RESULTS
Of the 279 enrolled patients (178 men; median age, 76 y), the mortality rate was 12.2% (34/279). Univariate analysis showed a higher frequency of dementia in patients who died in hospital than that in surviving patients. Multivariate stepwise logistic analysis showed that dementia was significantly associated with higher rates of in-hospital mortality (odds ratio, 3.20; 95% confidence interval, 1.15-8.88, p = 0.026). In addition, subgroup survival curves showed that dementia was associated with reduced survival rates, even after adjusting for age (log-rank test, p = 0.0007).
CONCLUSIONS CONCLUSIONS
The comorbidity of dementia with pulmonary TB was associated with patient in-hospital mortality. Medical practitioners should be aware of dementia in patients with smear-positive pulmonary TB to identify high-mortality groups.

Identifiants

pubmed: 30760407
pii: S2212-5345(18)30247-8
doi: 10.1016/j.resinv.2019.01.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

354-360

Informations de copyright

Copyright © 2019 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Auteurs

Masafumi Saiki (M)

Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan; Department of Internal Medicine II, University of Yamanashi Faculty of Medicine, Japan; Division of Pulmonary Medicine, Jichi Medical University, Japan.

Yuki Iijima (Y)

Lung Cancer and Respiratory Disease Center, Yamanashi Prefectural Central Hospital, Japan; Division of Pulmonary Medicine, Jichi Medical University, Japan.

Takayuki Honda (T)

Department of Respiratory Medicine, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8510, Japan; Division of Pulmonary Medicine, Jichi Medical University, Japan. Electronic address: hondpulm@tmd.ac.jp.

Sayaka Mori (S)

Emergency Department, Yamanashi Prefectual Central Hospital, Japan; Division of Pulmonary Medicine, Jichi Medical University, Japan.

Toshiharu Tsutsui (T)

Lung Cancer and Respiratory Disease Center, Yamanashi Prefectural Central Hospital, Japan; Division of Pulmonary Medicine, Jichi Medical University, Japan.

Yoshinori Uchida (Y)

Lung Cancer and Respiratory Disease Center, Yamanashi Prefectural Central Hospital, Japan; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan; Division of Pulmonary Medicine, Jichi Medical University, Japan.

Yoichi Kobayashi (Y)

Lung Cancer and Respiratory Disease Center, Yamanashi Prefectural Central Hospital, Japan; Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan; Division of Pulmonary Medicine, Jichi Medical University, Japan.

Yumiko Kakizaki (Y)

Lung Cancer and Respiratory Disease Center, Yamanashi Prefectural Central Hospital, Japan; Division of Pulmonary Medicine, Jichi Medical University, Japan.

Hiroyuki Sakashita (H)

Department of Clinical Oncology, Tokyo Medical and Dental University, Japan; Division of Pulmonary Medicine, Jichi Medical University, Japan.

Yasunari Miyazaki (Y)

Department of Respiratory Medicine, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8510, Japan; Division of Pulmonary Medicine, Jichi Medical University, Japan.

Yoshihiro Miyashita (Y)

Lung Cancer and Respiratory Disease Center, Yamanashi Prefectural Central Hospital, Japan; Division of Pulmonary Medicine, Jichi Medical University, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH